| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
|
Medicine details |
|
| Medicine name | atezolizumab (Tecentriq®) |
| Formulation | 1,200mg concentrate for solution for infusion |
| Reference number | 3319 |
| Indication | In combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 01/08/2019 |
| NICE guidance | |
| Commercial arrangement | PAS |